These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

243 related articles for article (PubMed ID: 25684486)

  • 1. Roles of immunohistochemical staining in diagnosing pulmonary squamous cell carcinoma.
    Yan Y; Zhang YX; Fang WF; Kang SY; Zhan JH; Chen N; Hong SD; Liang WH; Tang YN; He DC; Wu X; Zhang L
    Asian Pac J Cancer Prev; 2015; 16(2):551-7. PubMed ID: 25684486
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Refining the diagnosis and EGFR status of non-small cell lung carcinoma in biopsy and cytologic material, using a panel of mucin staining, TTF-1, cytokeratin 5/6, and P63, and EGFR mutation analysis.
    Nicholson AG; Gonzalez D; Shah P; Pynegar MJ; Deshmukh M; Rice A; Popat S
    J Thorac Oncol; 2010 Apr; 5(4):436-41. PubMed ID: 20068475
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The importance of EGFR mutation testing in squamous cell carcinoma or non-small cell carcinoma favor squamous cell carcinoma diagnosed from small lung biopsies.
    Ho HL; Kao HL; Yeh YC; Chou TY
    Diagn Pathol; 2019 Jun; 14(1):59. PubMed ID: 31221183
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Chromogenic immunohistochemical quadruplex provides accurate diagnostic differentiation of non-small cell lung cancer.
    Roberts EA; Morrison LE; Behman LJ; Draganova-Tacheva R; O'Neill R; Solomides CC
    Ann Diagn Pathol; 2020 Apr; 45():151454. PubMed ID: 31923744
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Parallel FISH and immunohistochemical studies of ALK status in 3244 non-small-cell lung cancers reveal major discordances.
    Cabillic F; Gros A; Dugay F; Begueret H; Mesturoux L; Chiforeanu DC; Dufrenot L; Jauffret V; Dachary D; Corre R; Lespagnol A; Soler G; Dagher J; Catros V; Le Calve M; Merlio JP; Belaud-Rotureau MA
    J Thorac Oncol; 2014 Mar; 9(3):295-306. PubMed ID: 24518086
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Novel epidermal growth factor receptor mutation-specific antibodies for non-small cell lung cancer: immunohistochemistry as a possible screening method for epidermal growth factor receptor mutations.
    Kato Y; Peled N; Wynes MW; Yoshida K; Pardo M; Mascaux C; Ohira T; Tsuboi M; Matsubayashi J; Nagao T; Ikeda N; Hirsch FR
    J Thorac Oncol; 2010 Oct; 5(10):1551-8. PubMed ID: 20697298
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mutation profile and programmed death ligand 1 status of patients with non-small cell lung cancer diagnosed with "adenocarcinoma" and "non-small cell carcinoma favor adenocarcinoma".
    Shigeta N; Yokose T; Murakami S; Isaka T; Shinada K; Yoshioka E; Narita A; Katakura K; Kondo T; Kato T; Nagashima T; Saito H; Ito H
    Thorac Cancer; 2024 Feb; 15(6):458-465. PubMed ID: 38197164
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Significance of epidermal growth factor receptor gene mutations in squamous cell lung carcinoma.
    Miyamae Y; Shimizu K; Hirato J; Araki T; Tanaka K; Ogawa H; Kakegawa S; Sugano M; Nakano T; Mitani Y; Kaira K; Takeyoshi I
    Oncol Rep; 2011 Apr; 25(4):921-8. PubMed ID: 21318227
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The Use of Immunohistochemistry Improves the Diagnosis of Small Cell Lung Cancer and Its Differential Diagnosis. An International Reproducibility Study in a Demanding Set of Cases.
    Thunnissen E; Borczuk AC; Flieder DB; Witte B; Beasley MB; Chung JH; Dacic S; Lantuejoul S; Russell PA; den Bakker M; Botling J; Brambilla E; de Cuba E; Geisinger KR; Hiroshima K; Marchevsky AM; Minami Y; Moreira A; Nicholson AG; Yoshida A; Tsao MS; Warth A; Duhig E; Chen G; Matsuno Y; Travis WD; Butnor K; Cooper W; Mino-Kenudson M; Motoi N; Poleri C; Pelosi G; Kerr K; Aisner SC; Ishikawa Y; Buettner RH; Keino N; Yatabe Y; Noguchi M
    J Thorac Oncol; 2017 Feb; 12(2):334-346. PubMed ID: 27998793
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Synchronous overexpression of epidermal growth factor receptor and HER2-neu protein is a predictor of poor outcome in patients with stage I non-small cell lung cancer.
    Onn A; Correa AM; Gilcrease M; Isobe T; Massarelli E; Bucana CD; O'Reilly MS; Hong WK; Fidler IJ; Putnam JB; Herbst RS
    Clin Cancer Res; 2004 Jan; 10(1 Pt 1):136-43. PubMed ID: 14734462
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Is the current diagnostic algorithm reliable for selecting cases for EGFR- and KRAS-mutation analysis in lung cancer?
    Vincenten JP; Smit EF; Grünberg K; Postmus PE; Snijders PJ; Witte BI; Heideman DA; Thunnissen E
    Lung Cancer; 2015 Jul; 89(1):19-26. PubMed ID: 25982011
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Suitability of thoracic cytology for new therapeutic paradigms in non-small cell lung carcinoma: high accuracy of tumor subtyping and feasibility of EGFR and KRAS molecular testing.
    Rekhtman N; Brandt SM; Sigel CS; Friedlander MA; Riely GJ; Travis WD; Zakowski MF; Moreira AL
    J Thorac Oncol; 2011 Mar; 6(3):451-8. PubMed ID: 21266922
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clarifying the spectrum of driver oncogene mutations in biomarker-verified squamous carcinoma of lung: lack of EGFR/KRAS and presence of PIK3CA/AKT1 mutations.
    Rekhtman N; Paik PK; Arcila ME; Tafe LJ; Oxnard GR; Moreira AL; Travis WD; Zakowski MF; Kris MG; Ladanyi M
    Clin Cancer Res; 2012 Feb; 18(4):1167-76. PubMed ID: 22228640
    [TBL] [Abstract][Full Text] [Related]  

  • 14. p40 & thyroid transcription factor-1 immunohistochemistry: A useful panel to characterize non-small cell lung carcinoma-not otherwise specified (NSCLC-NOS) category.
    Walia R; Jain D; Madan K; Sharma MC; Mathur SR; Mohan A; Iyer VK; Kumar L
    Indian J Med Res; 2017 Jul; 146(1):42-48. PubMed ID: 29168459
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Subtyping of undifferentiated non-small cell carcinomas in bronchial biopsy specimens.
    Loo PS; Thomas SC; Nicolson MC; Fyfe MN; Kerr KM
    J Thorac Oncol; 2010 Apr; 5(4):442-7. PubMed ID: 20195168
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Hsp90AB1 Protein is Overexpressed in Non-small Cell Lung Cancer Tissues 
and Associated with Poor Prognosis in Lung Adenocarcinoma Patients].
    Wang M; Feng L; Li P; Han N; Gao Y; Xiao T
    Zhongguo Fei Ai Za Zhi; 2016 Feb; 19(2):64-9. PubMed ID: 26903158
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Histologic subtyping of poorly-differentiated solid lung cancer with molecular testing for epidermal growth factor receptor mutation and ALK gene rearrangement: an analyses of 167 cases].
    Fang F; Wang YX; Hu ST; Yang L; Di J; Liu DG; Lyu N
    Zhonghua Bing Li Xue Za Zhi; 2018 Jun; 47(6):432-437. PubMed ID: 29886587
    [No Abstract]   [Full Text] [Related]  

  • 18. [Diagnosis of lung biopsy employing the 2015 WHO criteria and detection of related oncogenic driver mutations].
    Fang F; Qiao XB; Yang L; Di J; Hu ST; Liu DG; Lyu N
    Zhonghua Bing Li Xue Za Zhi; 2019 Apr; 48(4):270-275. PubMed ID: 30955261
    [No Abstract]   [Full Text] [Related]  

  • 19. Detection of EML4-ALK fusion genes in non-small cell lung cancer patients with clinical features associated with EGFR mutations.
    Shaozhang Z; Xiaomei L; Aiping Z; Jianbo H; Xiangqun S; Qitao Y
    Genes Chromosomes Cancer; 2012 Oct; 51(10):925-32. PubMed ID: 22736493
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Subtyping of non-small cell lung carcinoma: a comparison of small biopsy and cytology specimens.
    Sigel CS; Moreira AL; Travis WD; Zakowski MF; Thornton RH; Riely GJ; Rekhtman N
    J Thorac Oncol; 2011 Nov; 6(11):1849-56. PubMed ID: 21841504
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.